Asthma is a heterogeneous respiratory disease characterized by usually reversible
bronchial obstruction, which is clinically expressed by different phenotypes driven by …

Type 2-immunity represents the typical adaptive response to allergen exposure in atopic
individuals. It mainly involves Th2 cells and immunoglobulin E, as the main orchestrators of …

Background Assessment of clinical outcomes in the real-world corroborates findings from
randomized controlled trials (RCTs). Objective This meta-analysis evaluated real-world data …

Commensal bacteria that colonize mammalian barrier surfaces are reported to influence T
helper type 2 (TH2) cytokine-dependent inflammation and susceptibility to allergic disease …

Omalizumab was the first, and for a long time the only available monoclonal antibody for the
add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets …

Asthma and nasal polyposis often coexist and are frequently intertwined by tight pathogenic
links, mainly consisting of the cellular and molecular pathways underpinning type 2 airway …

Current asthma therapy is based on the use of adrenergic bronchodilator and anti-
inflammatory drugs the specificity, efficacy, duration of action, and safety of which have been …

We previously reported the French real-life experience of 1 year of add-on treatment with
omalizumab in 101 severe allergic asthmatic children (6–18 years), 92 of whom were still …

Omalizumab has been shown to be an effective add-on therapy for patients with
uncontrolled severe persistent allergic asthma. There has been a steady accumulation of …

Background. The wide availability of monoclonal antibodies for the add-on therapy of severe
asthma currently allows for the personalization of biologic treatment by selecting the most …